Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade

Journal of Pathology

Volumn 194, Issue 3, 2001, Pages 327-333

  Mommers, Ellen C M ^a   Leonhart, Angelique M ^a   Falix, Farah ^a   Michalides, Rob ^b   Meijer, Chris J L M ^a   Baak, Jan P A ^c   Van Diest, Paul J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

Apoptosis; Breast cancer; DCIS; Hyperplasia; Proliferation

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST HYPERPLASIA; CANCER GRADING; CANCER GROWTH; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; ONCOGENE NEU; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL CYCLE PROTEINS; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034940095     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.910     Document Type: Article

References (45)

1. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
2. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
3. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis
4. Accumulation of p53 tumour suppressor gene protein: An independent marker of prognosis in breast cancers
5. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer
6. p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival
7. Decreased levels of the cell-cycle inhibitor p27 Kip1 protein: Prognostic implications in primary breast cancer
8. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value
9. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer
10. Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas
11. The transition from hyperplasia to invasive carcinoma of the breast
12. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways
13. Ductal carcinoma in situ in breast carcinogenesis
14. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ)
15. Invasive ductal carcinoma accompanied by ductal carcinoma in situ (DCIS): Comparison of DCIS grade with grade of invasive component
16. Correlation of numerical and structural status of chromosome 16 with histological type and grade of non-invasive and invasive breast carcinomas
17. Balance of cell proliferation and apoptosis in breast carcinogenesis
18. p53 protein expression and nuclear DNA content in breast intraductal proliferations
19. Bcl-2 expression in the spectrum of preinvasive breast lesions
20. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: An immunohisto-chemical study
21. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67
22. Neu over-expression correlates with extent of disease in large cell ductal carcinoma in situ of the breast
23. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
24. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast
25. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast
26. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast
27. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast
28. Epithelial hyperplasia
29. Ductal carcinoma in situ: A proposal for a new classification
30. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
31. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats
32. Risk factors for breast cancer in women with proliferative breast disease
33. A prospective study of the development of breast cancer in 16,692 women with benign breast disease
34. A comparative morphometric and cytophotometric study of intraductal hyperplasia and intraductal carcinoma of the breast
35. Atypical ductal hyperplasia of the breast: Clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p
36. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
37. Benign, preinvasive and invasive ductal breast lesions. A comparative study with quantitative techniques: Morphometry, image-, and flow cytometry
38. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast
39. Inhibitors of mammalian G1 cyclin-dependent kinases
40. G1 cyclins and control of the cell division cycle in normal and transformed cells
41. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
42. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
43. Prognostic significance of TP53 alterations in breast carcinoma
44. The p53 tumour suppressor gene
45. p53 function and dysfunction